1. Albers P et al. Guidelines on testicular cancer. Eur Urol 2005; 48: 885-94.
2. Krege S et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 2008; 53: 497-513.
3. Beck SDW, Foster RS. Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer. World J Urol 2006; 24: 267-72.
4. Oldenburg J et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003; 21: 3310-17.
5. Pfister D et al. Pathohistological findings in patients with nonseminomatous germ cell tumours who undergo postchemotherapy retroperitoneal lymph node dissection for small tumours. J Urol 2011; 185 (Suppl): AUA 2011, Abstract #830.
6. Kollmannsberger C et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 2010; 28: 537-42.
7. Ehrlich Y et al. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: Is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010; 28: 531-6.
8. Gerl A et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997; 8: 41-7.
9. Debono DJ et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumours. J Clin Oncol 1997; 15: 1455-64.
10. Capitanio U et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology 2009; 74: 373-7.
11. Fléchon A et al. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int 2010; 106: 779-85.
12. Fléchon A et al. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 1979; 168: 1975-9.
13. Friedman EL et al. Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 1985; 3: 1325-32.
14. Schultz SM et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989; 7: 1497-503.
15. Fosså SD et al. The treatment of advanced metastatic seminoma: Experience in 55 cases. J Clin Oncol 1987; 5: 1071-7.
16. Ravi R et al. Integrated approach to the management of patients with advanced germ cell tumors of the testis. J Surg Oncol 1994; 55: 47-51.
17. Puc HS et al. Management of residual mass in advanced seminoma: Results and recommendations from the Memorial Sloan Kettering Cancer Center. J Clin Oncol 1996; 14: 454-60.
18. Pfister D et al. Reduced morbidity in resection of residual tumors after chemotherapy for seminoma. Urologe A 2015; 54: 1402-6.
19. Mosharafa AA et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 2003; 169: 2126-8.
20. De Santis M et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: An update from the multicenter SEMPET trial. J Clin Oncol 2004; 22: 1034-9.
21. Becherer A et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 2005; 54: 284-8.
22. Albers P et al.; German Testicular Cancer Study Group. Prediction of necrosis after chemotherapy of advanced germ cell tumors: Results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 2004; 171: 1835-8.
23. Kamat MR et al. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J Surg Oncol 1992; 51: 65-7.
24. Hofmockel G et al. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int 1996; 57: 38-42.
25. Herr HW et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997; 157: 860-2.
26. Fossa SD et al. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989; 141: 557-9.
27. Toner GC et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 1990; 8: 1683-94.
28. Aprikian AG et al. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 1994; 74: 1329-34.
29. Herr HW. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol 1997; 80: 653-7.
30. Wood DP et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 1992; 148: 1812-6.
31. Rabbani F et al. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: Is a modified dissection and resection of the residual mass sufficient? Br J Urol 1998; 81: 295-300.
32. Heidenreich A. Residual tumor resection following inductive chemotherapy in advanced testicular cancer. Eur Urol 2007; 51: 299-301.
33. Albers P et al. Thoracoabdominal resection of retrocrural residual tumors. Akt Urol 2004; 35: 141-50.
34. Fujioka T et al. Retroperitoneal lymph node dissection for testicular tumors using the thoracoabdominal approach. Int Surg 1993; 78: 154-8.
35. Skinner DG et al. Complications of thoracoabdominal retroperitoneal lymph node dissection. J Urol 1982; 127: 1107-10.
36. Hartmann JT et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 1997; 33: 843-7.
37. Besse B et al. Nonseminomatous germ cell tumors: Assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg 2009; 137: 448-52.
38. Jacobsen NE etal. Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? J Urol 2010; 184: 949-53.
39. Beck SD et al. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. J Urol 2001; 165: 1517-20.
40. Christmas TJ et al. Vascular interventions during post-chemotherapy retroperitoneal lymph node dissection for metastatic testis cancer. Eur J Surg Oncol 1998; 24: 292-7.
41. Beck SD, Lalka SG. Long-term results after inferior vena cava resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg 1998; 28: 808-14.
42. Heidenreich A et al. Evaluation of the inferior vena cava by magnetic resonance imaging in advanced testicular germ cell tumors. Eur Urol 1998; 49: 196.
43. Winter C et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: A multicenter analysis of the German Testicular Cancer Study Group. Eur Urol 2012; 61: 403-9.
44. Hendry WF et al. Metastatic nonseminomatous germ cell tumors of the testis: Results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 2002; 94: 1668-76.
45. Spiess PE et al. Surgical management of growing teratoma syndrome: The M. D. Anderson Cancer Center experience. J Urol 2007; 177: 1330-4.
46. Logothetis CJ et al: The growing teratoma syndrome. Cancer 1982; 50: 1629-35.
47. Andre F et al: The growing teratoma syndrome: Results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000; 36: 1389-94.
48. Sonneveld DJ et al. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: A plea for an aggressive surgical approach. Cancer 1998; 82: 1343-51.
49. Qvist HL et al. Post-chemotherapy tumor residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses? J Urol 1991; 145: 300-2.
50. Beck SD et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 2007; 110: 1235-40.
51. Cho JS et al. Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: A long-term update. BJU Int 2017; 120: 104-8.
52. Heidenreich A et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: Radical or modified template resection. Eur Urol 2009; 55: 217-24.
53. Vallier C et al. External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer. World J Urol 2014; 32: 1573-8.
54. Eggener SE et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimes for metastatic testicular germ cell tumors. Cancer 2007; 109: 528-35.
55. Waples MJ, Messing EM. Redo retroperitoneal lymphadenectomy for germ cell tumor. Urology 1993; 42: 1-4.
56. Cespedes RD, Peretsman SJ. Retroperitoneal recurrences after retroperitoneal lymph node dissection for low-stage nonseminomatous germ cell tumors. Urology 1999; 54: 548-52.
57. Sexton WJ et al. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol 2003; 169: 1353-6.
58. McKiernan JM et al. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: Clinical presentation, patterns of recurrence and outcome. Urology 2003; 62: 732-6.
59. Heidenreich A et al. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol 2005; 47: 64-71.
60. Albers P et al. Salvage surgery of chemorefractory germ cell tumors with elevated markers. J Urol 2000; 164: 381-4.
61. Beck SD et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2005; 23: 6149-56.
62. Nash PA et al. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: Indications, implications and outcomes. J Urol 1998; 159: 707-10.
63. Stephenson AJ et al. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol 2006; 176: 1996-9.
64. Heidenreich A et al. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol 2017; 28: 362-7.
65. Heidenreich A et al. Complications of primary nerve-sparing lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: Experience of the German Testicular Cancer Study Group. J Urol 2003; 169: 1710-4.
66. Mosharafa AA et al. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 2004; 171: 1839-41.
67. Leibovitch I et al. The diagnosis and management of postoperative chylous ascites. J Urol 2002; 167: 449-57
